Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Nikbakht S et al
Will I always feel sick on GLP-1 medication
The existing evidence base consists primarily of: Small observational studies in patients with diabetes who also have inflammatory conditions Mechanistic studies exploring theoretical anti-inflammatory pathways Indirect evidence from cardiovascular outcome trials showing reduced inflammatory markers in people with type 2 diabetes (which cannot be extrapolated to rheumatoid arthritis or to microdosing) NICE guidance for rheumatoid arthritis management (NG100) does not include GLP-1 receptor agonists among recommended treatment options
It is an alternative to harsh ingredients that can cause redness or irritate the face
GLP-1 receptor agonist injections, such as Mounjaro and Wegovy, are supported by robust clinical evidence, demonstrating 15-25% weight loss in trials
According to the FDA, these include medullary thyroid cancer and inflammation of the pancreas, or pancreatitis
